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iabetes Mellitus Does Not
nsweeten Left Main
ntervention*
avid O. Williams, MD,† J. Dawn Abbott, MD‡
oston, Massachusetts; and Providence, Rhode Island
ndreas Gruentzig frowned on balloon angioplasty for
nprotected left main coronary artery (LMCA) disease.
ne of his earliest cases was such a patient. And why not?
uring the early years, the paramount challenge for balloon
ngioplasty was achieving acute success—namely, dilating
he lesion. Reaching and crossing a lesion were the most
emanding parts of the procedure. Given this, the left main
ith its proximity and short, straight course was a natural
arget. His first left main attempt was successful, for the
hort term. Despite relief of angina and normalization of his
tress test, the patient died suddenly early in follow-up.
esion recurrence was the putative culprit, and subsequently
MCA angioplasty was contraindicated, because restenosis
ight express itself as sudden death.
See page 956
Over the last several years, our view of unprotected
MCA percutaneous coronary intervention (PCI) has
hanged. There have been several large observational reports
f consecutive patients, carefully selected and treated with
efined stenting technique, that demonstrate 1-year mortal-
ty rates as low as 4.8%. Importantly, in-hospital mortality
ates are 0% in many series, indicating that the real concern
or untoward events related to LMCA PCI resides in the
eriod of follow-up (1,2).
More recently, the SYNTAX (Synergy between Percu-
aneous Coronary Intervention with Taxus and Cardiac
urgery) randomized study confirmed these favorable out-
omes in patients with LMCA disease (3). In patients
andomized to PCI the peri-procedural death rate was
.1%, and 1-year mortality was 4.4%. The SYNTAX
nvestigators made several significant observations about
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the †Division of Cardiovascular Medicine, Brigham and Women’s Hospital,n
oston, Massachusetts; and the ‡Division of Cardiology, Rhode Island Hospital,
rovidence, Rhode Island. Dr. Williams is a consultant for Cordis.nprotected LMCA disease. First, in the subset of patients
hat had LMCA disease, there was no significant difference
n composite rate of major adverse cardiac or cerebrovascular
vents at 1 year between the PCI and coronary artery bypass
rafting (CABG) groups (15.8% vs. 13.7%, p  0.44,
espectively). Rates of repeat revascularization, however,
ere significantly higher among PCI patients (11.8% vs.
.5%, p  0.02), whereas stroke was more common among
ABG patients. These data support the use of PCI with
rug-eluting stents (DES) as a reasonable alternative to
ABG for patients with LMCA disease. A second obser-
ation, however, qualifies this conclusion. When SYNTAX
nvestigators analyzed outcomes according to LMCA dis-
ase involvement and the extent of associated coronary
isease, they identified a relationship between disease dis-
ribution and PCI outcome. For unprotected LMCA pa-
ients with limited disease (i.e., 0- or 1-vessel disease), the
bserved rates of adverse events at 12 months trended lower
n the PCI group than in the CABG group. For patients
ith unprotected LMCA and 2- or 3-vessel disease, the
pposite was true, with rates of adverse events higher in PCI
atients. In summary, the SYNTAX study did not identify
safety concern of PCI for unprotected LMCA for up to 12
onths of follow-up. The primary shortcoming of PCI
uring this period was the excessive need for a repeat
evascularization procedure. Of note, 25% of patients in the
YNTAX trial had diabetes mellitus.
The presence of diabetes mellitus has influenced the
omparative effectiveness of PCI and CABG. In the BARI
Bypass Angioplasty Revascularization Investigation), mul-
ivessel coronary artery disease patients with diabetes who
ere randomly assigned to PCI had a higher 5-year mor-
ality rate than similar patients assigned to CABG. Further-
ore, in the absence of diabetes, rates of death and
yocardial infarction (MI) were independent of revascular-
zation strategy (4). On the contrary, patients in the BARI
egistry did not demonstrate this influence of diabetes on
utcome (5). These findings might be explained by the
elative contribution of patient factors, anatomic disease
everity, and physician judgment in recommending an
ppropriate revascularization strategy.
In this issue of JACC: Cardiovascular Interventions, Kim
t al. (6) report on the influence of diabetes on the outcomes
f unprotected LMCA patients treated with either DES or
ABG within the MAIN-COMPARE (Revitalization for
nprotected Left Main Coronary Artery Stenosis: Com-
arison of Percutaneous Coronary Angioplasty versus Sur-
ical Revascularization) registry (2). This is a particularly
elevant topic. First, patients with diabetes are more likely to
xperience restenosis, a potentially fatal event for those with
nprotected LMCA disease treated by PCI. Second, dia-
etes is associated with more advanced and complex coro-
ary artery disease, a setting wherein PCI is less effective.
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965In their registry of 1,474 patients, 507 had diabetes. Kim
t al. (6) found meaningful differences in the distribution of
aseline features between the PCI and CABG groups, for
he most part indicating CABG patients had more severe
isease. Such an imbalance and the nonrandomized study
esign substantially limit our ability to directly compare the
ffectiveness and safety of the 2 revascularization options.
s expected, unadjusted rates of death, MI, stroke, and
arget vessel revascularization (TVR) were higher at 3 years
n patients with diabetes compared with those without.
mong patients with diabetes, there were no differences in
stimated, unadjusted rates of death, Q-wave MI, or stroke
ccording to revascularization treatment. As usual, there
as a substantial difference in TVR favoring CABG (2.0%
s. 11.2%, p  0.001). Importantly, however, the signifi-
antly higher rate of TVR with PCI was also observed in
atients without diabetes mellitus, suggesting that addi-
ional factors are responsible for the increased rate of TVR
n PCI patients. This is supported by the finding that
reatment effects for PCI and CABG did not vary according
o diabetes status. After statistical adjustment, differences in
utcomes were similar. Thus, with repeat revascularization
side, PCI can provide a safe alternative to CABG for a
ubstantial proportion of patients with unprotected LMCA
isease and diabetes.
It is important to consider case selection, when putting
he study results in perspective. An interesting observation is
hat diabetes status seemed to play only a minor role in
etermining whether PCI or CABG was selected as the
nitial revascularization strategy in this group of registry
atients. Of the 507 patients with diabetes, 50% of patients
eceived DES, and 50% underwent CABG. In nondiabetic
atients, DES was chosen only slightly more frequently at
5%, with 45% undergoing CABG. This observation is not
ntirely new. A prior study in stable angina patients found
hat treatment decisions regarding the choice for CABG or
CI were not influenced by the presence of diabetes (7). In
he BARI type-2 diabetes trial (8), selection of CABG over
CI was declared in 44% of patients and was driven
rimarily by characteristics determined by the coronary
ngiogram.
Both anatomic and patient-related factors have been
hown to influence the outcome of unprotected LMCA
isease PCI, and although we are not provided the details
egarding treatment decisions in this study, the data speak
o these issues. Prior unprotected LMCA PCI studies
bserved a high mortality rate in high-risk patients as
etermined by the European system for cardiac operative
isk evaluation (Euroscore) (9,10). In this study, the Euro-
core was higher in patients chosen for CABG compared
ith PCI. With respect to anatomic factors, PCI patients
ith isolated unprotected LMCA disease and those with- tstial or proximal LMCA disease have much better out-
omes than those with complex distal LMCA bifurcation or
ssociated multivessel disease, where a disproportionately
igh incidence of restenosis has been observed (1,3,11,12).
n the current study, PCI patients were more likely to have
solated LMCA disease. Although ostial and mid shaft
isease was less common in the PCI patients, those with
istal bifurcation disease involvement less often had involve-
ent of both the ostial left anterior descending and left
ircumflex coronary arteries. In other words, among the PCI
atients, the distal LMCA disease was less complex. This is
onfirmed by the low number of stents used (1.3  0.6) in
hose with diabetes.
A final comment is that the influence of post-PCI
urveillance cannot be overlooked and that outcomes must
lways be interpreted within the context that they are
athered and reported. For a registry study where individual
hysicians are responsible for clinical follow-up, there might
e tremendous variation in the frequency and modalities of
ost-PCI evaluation. A shortcoming is that we are not
rovided with information on the number of patients that
nderwent routine surveillance angiography or the indica-
ion for repeat revascularization. The majority of TVR
vents in the PCI patients seem to occur between 6 and 12
onths. There are many physicians that believe that unpro-
ected LMCA PCI patients should be followed with routine
ngiography during the first year, and this has been consid-
red acceptable in the PCI guidelines (13). Surveillance
ngiography in unprotected LMCA PCI increases TVR
12), as is the case in other PCI scenarios. Nevertheless, the
-year rates of PCI reported by Kim et al. (6) are more than
cceptable and in line with the SYNTAX trial.
How does this report affect our current indications for
electing PCI or CABG for an individual patient with
nprotected LMCA disease? The current American College
f Cardiology/American Heart Association/Society for
ardiovascular Angiography and Interventions guidelines
tate that CABG is the preferred revascularization approach
or such patients and that PCI should only be offered when
urgery is not feasible or excessively hazardous (13). It is
ikely that enough evidence exists to warrant a change in this
ecommendation, on the basis of multiple observational
tudies, the SYNTAX study, and personal experiences. It
eems reasonable to offer PCI to selected unprotected
MCA disease patients with minimal associated vessel
isease and simple lesions. Presence of diabetes should not
ffect this decision. This recommendation is tempered,
owever, in that legitimate comparative long-term data are
ot available. Moreover, we should not hastily abandon this
stablished method of revascularization, given the recog-
ized survival benefit of CABG for patients with unpro-
ected LMCA disease.
R
l
p
d
R
1
1
1
1
K
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 1 0 , 2 0 0 9
O C T O B E R 2 0 0 9 : 9 6 4 – 6
Williams and Abbott
Editorial Comment
966eprint requests and correspondence: Dr. David O. Wil-
iams, Cardiovascular Medicine, Brigham and Woman’s Hos-
ital, 75 Francis Street, Boston, Massachusetts 02115. E-mail:
owilliams@partners.org.
EFERENCES
1. Chieffo A, Park SJ, Valgimigli M, et al. Favorable long-term outcome
after drug-eluting stent implantation in nonbifurcation lesions that
involve unprotected left main coronary artery: a multicenter registry.
Circulation 2007;116:158–62.
2. Seung KB, Park D-W, Kim Y-H, et al. Stents versus coronary-artery
bypass grafting for left main coronary artery disease. N Engl J Med
2008;358:1781–92.
3. Serruys PW, Morice M-C, Kappetein AP, et al. Percutaneous coronary
intervention versus coronary-artery bypass grafting for severe coronary
artery disease. N Engl J Med 2009;360:961–72.
4. Comparison of coronary bypass surgery with angioplasty in patients
with multivessel disease. The Bypass Angioplasty Revascularization
Investigation (BARI) Investigators. N Engl J Med 1996;335:217–25.
5. Feit F, Brooks MM, Sopko G, et al., BARI Investigators. Long-term
clinical outcome in the Bypass Angioplasty Revascularization Investi-
gation Registry: comparison with the randomized trial. Circulation
2000;101:2795–802.
6. Kim W-J,, Park D-W, Yun S-C, et al. Impact of diabetes mellitus on
the treatment effect of percutaneous or surgical revascularization for
patients with unprotected left main coronary artery disease: a subgroup
analysis of the MAIN-COMPARE study. J Am Coll Cardiol Intv
2009;2:956–63. d7. Breeman A, Bertrand ME, Ottervanger JP, et al. Diabetes does not
influence treatment decisions regarding revascularization in patients
with stable coronary artery disease. Diabetes Care 2006;29:2003–11.
8. Kim LJ, King I, Spencer B, et al. Factors related to the selection of
surgical versus percutaneous revascularization in diabetic patients with
multivessel coronary artery disease in the BARI 2D (Bypass Angio-
plasty Revascularization Investigation in Type 2 Diabetes) trial. J Am
Coll Cardiol Intv 2009;2:384–92.
9. Wood FO, Saylors EK, Schneider JE, Jobe RL, Mann JT III.
Unprotected left main disease managed with drug-eluting stents:
long-term outcome of 100 patients with increased surgical risk. Cath
Cardiovasc Int 2008;71:533–8.
0. Migliorini A, Moschi G, Giurlani L, et al. Drug-eluting stent
supported percutaneous coronary intervention for unprotected left main
disease. Cath Cardiovasc Int 2006;68:225–30.
1. Valgimigli M, Malagutti P, Rodriguez-Granillo GA, et al. Distal left
main coronary disease is a major predictor of outcome in patients
undergoing percutaneous intervention in the drug-eluting stent era: an
integrated clinical and angiographic analysis based on the Rapamycin-
Eluting Stent Evaluated At Rotterdam Cardiology Hospital
(RESEARCH) and Taxus-Stent Evaluated At Rotterdam Cardiology
Hospital (T-SEARCH) registries. J Am Coll Cardiol 2006;47:1530–7.
2. Price MJ, Cristea E, Sawhney N, et al. Serial angiographic follow-up of
sirolimus-eluting stents for unprotected left main coronary artery
revascularization. J Am Coll Cardiol 2006;47:871–7.
3. Smith SC Jr., Feldman TE, Hirshfeld JW Jr., et al. ACC/AHA/SCAI
2005 guideline update for percutaneous coronary intervention: a report
of the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Com-
mittee to Update 2001 Guidelines for Percutaneous Coronary Inter-
vention). J Am Coll Cardiol 2006;47:e1–121.
ey Words: diabetes mellitus  left main coronary artery
isease  stents  coronary artery bypass surgery.
